Moleculera Labs Education Series:

The Journal of Child and Adolescent Psychopharmacology

Treatment of Pediatric Acute-Onset Neuropsychiatric Disorder in a Large Survey Population

Treatment of Pediatric Acute-Onset Neuropsychiatric Disorder

This analysis of a retrospective online survey examines treatment histories and clinical outcomes in a large community of 698 PANS patients. The authors review the patient’s clinical response to aggressive antibiotic treatment, anti-inflammatory medications, immune modulators, psychotropic medications, and psychotherapy, along with complementary and alternative medicines. The effectiveness of various treatment modalities on patients with an immune deficiency is also discussed.


The Journal of Child and Adolescent Psychopharmacology

A Double-Blind Randomized Placebo-Controlled Pilot Study of Azithromycin in Youth with Acute-Onset Obsessive–Compulsive Disorder

Study of Azithromycin in Youth with Acute-Onset Obsessive–Compulsive Disorder

This study assesses the preliminary efficacy, tolerability, and safety of azithromycin compared with placebo in the treatment of Obsessive-Compulsive Disorder (OCD) and associated symptoms in children with Pediatric Acute-Onset Neuropsychiatric Syndrome (PANS). 1


Clinicians: Schedule a Personal Phone Call with Clinical Staff

If you have interest in knowing how the Cunningham Panel™ biomarkers (Dopamine D1R, Dopamine D2R, Lysoganglioside GM1, Tubulin and CaMKII) can assist in diagnosing treatable autoimmune encephalopathies characterized by abnormal neuropsychiatric behaviors, schedule an individual phone call with Moleculera Labs clinical staff by completing the information below, or call Amy Cross, RN, at 405-239-5254.